Notice of Proposed Sale · 144
Cytokinetics, Incorporated
CYTKNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- CYTOKINETICS, INCORPORATED
- Issuer CIK
- 0001061983
- SEC file number
- 000-50633
- Phone
- 6506243000
- Person for whose account securities are to be sold
- ANDREW CALLOS
- Relationships to issuer
- Officer
- Street
- 350 OYSTER POINT BOULEVARD
- City
- SOUTH SAN FRANCISCO
- State / country code
- CA
- Postal code
- 94080
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 24,000 | 1,881,240.00 | 124,432,565 | 07/30/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 07/30/2026 | Exercise of Stock Options | Issuer | 24,000 | N | 07/30/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| 10b5-1 Sales for ANDREW CALLOS | Common | 06/30/2026 | 15,000 | 1,287,069.00 |
| 10b5-1 Sales for ANDREW CALLOS | Common | 06/01/2026 | 15,000 | 1,111,237.50 |
| 10b5-1 Sales for ANDREW CALLOS | Common | 05/05/2026 | 11,333 | 875,474.25 |
| 10b5-1 Sales for ANDREW CALLOS | Common | 05/01/2026 | 15,857 | 1,030,705.00 |
Seller — prior-sale row 1, entry 1
- Name
- 10b5-1 Sales for ANDREW CALLOS
- Street
- 350 OYSTER POINT BOULEVARD
- City
- SOUTH SAN FRANCISCO
- State / country code
- CA
- Postal code
- 94080
Seller — prior-sale row 2, entry 1
- Name
- 10b5-1 Sales for ANDREW CALLOS
- Street
- 350 OYSTER POINT BOULEVARD
- City
- SOUTH SAN FRANCISCO
- State / country code
- CA
- Postal code
- 94080
Seller — prior-sale row 3, entry 1
- Name
- 10b5-1 Sales for ANDREW CALLOS
- Street
- 350 OYSTER POINT BOULEVARD
- City
- SOUTH SAN FRANCISCO
- State / country code
- CA
- Postal code
- 94080
Seller — prior-sale row 4, entry 1
- Name
- 10b5-1 Sales for ANDREW CALLOS
- Street
- 350 OYSTER POINT BOULEVARD
- City
- SOUTH SAN FRANCISCO
- State / country code
- CA
- Postal code
- 94080
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Notice signature
- Notice date
- 07/30/2026
- Signed
- /s/ Andrew Callos
- Plan adoption dates
- 09/05/2025
Company context
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the approved in the U.S., China, European Union and United Kingdom for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.